## Abstract Neurofibromatosis 2 (NF2) is a genetic disorder caused by mutational inactivation of the __NF2__ gene and is characterized by bilateral vestibular schwannomas, spinal tumors, and other benign tumors of the nervous system. Previously, we found intragenic __NF2__ mutations in 99 of 188 un
Screening for germ-line mutations in the NF2 Gene
✍ Scribed by Philippe Mérel; Khé Hoang-Xuan; Marc Sanson; Emilia Bijlsma; Guy Rouleau; Pierre Laurent-Puig; Stephan Pulst; Michael Baser; Gilbert Lenoir; Jean Marc Sterkers; Jacques Philippon; François Resche; Victor F. Mautner; Georges Fischer; Theo Hulsebos; Alain Aurias; Olivier Delattre; Gilles Thomas
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 876 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Neurofibromatosiis type 2 (NF2) is a monogenic dominantly inherited disease that predisposes t o the development of tumors of the nervous system, particularly meningiomas and schwannomas. The gene which, when altered, causes NF2, is localized on chromosome 22 and has recently been identified. The NF2 gene is also the site of somatic mutation in tumors, suggesting that it might have a turnor suppressor activity. We here report a screening method for the detection of point mutations in NF2 which takes advantage of denaturing gradient gel electrophoresis (DGGE). This method efficiently screens 95% of the coding sequence and 90% of introdexon junctions. When applied t o 9 I unrelated NF2 patients, it enabled the identification of 32 germ-line mutations. Since mutations are found in only one third of the patients, it is expected that mutations or deletions affecting the promoter and/or intronic regions of the NF2 gene occur frequently. The characterized mutations are preferentially located within the 5' half of the gene. Most of them are predicted to lead t o the synthesis of a truncated protein. A search for genotype/phenotype correlations showed that, at least in this series of patients, mild manifestations of the disease were associated with mutations which preserve the C-terminal end of the protein. Genes Chromosom Cancer I2: I 17-127 (1995).
📜 SIMILAR VOLUMES
Cystic fibrosis transmembrane conductance regulator (CFTR) gene studies are now one of the most frequent activities in clinical molecular genetics laboratories. The number of requests is growing, owing to the increasingly wide range of recognized CFTR gene diseases (cystic fibrosis, congenital bilat
By means of PCR-SSCP and direct sequencing, we detected 12 germ-line mutations of hMSH2 or hMLH1 in 37 Japanese hereditary non-polyposis colorectal cancer (HNPCC) kindreds, of whom 15 satisfied the Amsterdam and 22 the Japanese criteria. The germ-line mutation detection rate of hMSH2 was much higher
## Abstract Deletions of chromosome 22 have been identified in 3 types of childhood primary brain tumor: meningiomas, rhabdoid or atypical teratoid tumors (ATT) and ependymomas. This implicates the involvement of tumor suppressor genes on chromosome 22 in the genesis of these rare tumors. One such
## Abstract The __NF2__ gene is a putative tumor‐suppressor gene that, when it is altered in the germline, causes neurofibromatosis type 2, a tumor‐susceptibility disease that mainly predisposes to schwannomas and meningiomas. The recent isolation of the __NF2__ gene on chromosome 22 allows the ide